GSK新帅上任，开启“精细化”研发与并购新阶段

MedTrend医趋势02-05

GSK新任CEO Luke Miels在接替Emma Walmsley后，首次明确了他的管理风格：更激进的外部并购、更严苛的管线审查，以及向“以产品为中心”的转型。并购策略：寻找“隐藏在众目睽睽”的机会Miels 明确了GSK未来的交易逻辑，重点不再是单纯的大规模收购，而是精准的“补强型”收购（Bolt-on deals），理想的交易范围在20亿-40亿美元之间。筛选标准为那些定价合理、不一定属于...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2609530905?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-05 17:05","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2609530905","market":"us","top_or_hot":-1,"title":"GSK新帅上任，开启“精细化”研发与并购新阶段","media":"MedTrend医趋势","content":"<div>\n<p>GSK新任CEO Luke Miels在接替Emma Walmsley后，首次明确了他的管理风格：更激进的外部并购、更严苛的管线审查，以及向“以产品为中心”的转型。并购策略：寻找“隐藏在众目睽睽”的机会Miels 明确了GSK未来的交易逻辑，重点不再是单纯的大规模收购，而是精准的“补强型”收购（Bolt-on deals），理想的交易范围在20亿-40亿美元之间。筛选标准为那些定价合理、不一定属于...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205195933a4802856&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK新帅上任，开启“精细化”研发与并购新阶段</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK新帅上任，开启“精细化”研发与并购新阶段\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-05 17:05 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205195933a4802856&s=b><strong>MedTrend医趋势</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>GSK新任CEO Luke Miels在接替Emma Walmsley后，首次明确了他的管理风格：更激进的外部并购、更严苛的管线审查，以及向“以产品为中心”的转型。并购策略：寻找“隐藏在众目睽睽”的机会Miels 明确了GSK未来的交易逻辑，重点不再是单纯的大规模收购，而是精准的“补强型”收购（Bolt-on deals），理想的交易范围在20亿-40亿美元之间。筛选标准为那些定价合理、不一定属于...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205195933a4802856&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205195933a4802856&s=b","article_id":"2609530905","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205195933a4802856&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2609530905","pubTimestamp":1770282356,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"GSK新任CEO Luke Miels在接替Emma Walmsley后，首次明确了他的管理风格：更激进的外部并购、更严苛的管线审查，以及向“以产品为中心”的转型。并购策略：寻找“隐藏在众目睽睽”的机会Miels 明确了GSK未来的交易逻辑，重点不再是单纯的大规模收购，而是精准的“补强型”收购，理想的交易范围在20亿-40亿美元之间。近日，GSK确认将在英国和美国裁减数百名研发人员，旨在精简组织架构。2026 年，处于转型期的GSK销售预计增长3%-5%。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4532":"文艺复兴科技持仓","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4007":"制药","BK4588":"碎股","GSK.UK":"葛兰素史克","GSK":"葛兰素史克"},"translate_title":"GSK's new coach takes office, opening a new stage of \"refined\" R&D and mergers and acquisitions","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK.UK":0.6,"GSK":1.5},"content_text":"GSK新任CEO Luke Miels在接替Emma Walmsley后，首次明确了他的管理风格：更激进的外部并购、更严苛的管线审查，以及向“以产品为中心”的转型。并购策略：寻找“隐藏在众目睽睽”的机会Miels 明确了GSK未来的交易逻辑，重点不再是单纯的大规模收购，而是精准的“补强型”收购（Bolt-on deals），理想的交易范围在20亿-40亿美元之间。筛选标准为那些定价合理、不一定属于主流、但却“隐藏在众目睽睽之下”（hiding in plain sight）且价格合理的非主流资产。1月20日，GSK宣布约22亿美元收购美国临床阶段生物制药公司RAPT Therapeutics, Inc.全部股份，交易的核心是RAPT开发的长效抗免疫球蛋白E（IgE）单克隆抗体ozureprubart，它的研发起点来自于中国企业上海济煜医药。研发管线：更频繁、更冷酷的“大扫除”为了确保资源集中在最具潜力的项目上，Miels 开启了对研发管线的严厉审计。一方面，果断止损。宣布终止从 Affinivax 收购（21亿美元）获得的24价肺炎球菌疫苗（GSK5101955）的2期研发。另一方面，精简团队。近日，GSK确认将在英国和美国裁减数百名研发人员，旨在精简组织架构。应对“专利悬崖”与增长压力GSK目前面临严峻挑战，尤其是其核心业务——HIV药物（如Dolutegravir）将在2028年左右面临专利到期。2026 年，处于转型期的GSK销售预计增长3%-5%。尽管短期有压力，他仍坚持公司在2031年实现400亿英镑销售额的目标，这需要依赖目前的15项关键后期管线（包括呼吸合胞病毒疫苗 Arexvy 和乙肝药物 Bepirovirsen）的成功。参考文章：https://endpoints.news/gsks-new-ceo-eyes-more-dealmaking-intense-pipeline-inspection/","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609530905","isCrawlerRequest":true}